nach oben

07.05.2024 | REVIEW

CDK4/6 inhibitors: The Devil is in the Detail

verfasst von: Tara Magge, Sneha Rajendran, Adam M. Brufsky, Julia Foldi

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer.

Recent findings

Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy. In early BC, abemaciclib is the only currently approved agent while ribociclib has early positive clinical trial data. Toxicities and financial burden limit the use of CDK4/6i in all patients and resource-poor settings, and optimal timing of their use in mBC remains unclear.

Summary

There is considerable evidence for the use of CDK4/6i in metastatic and early HR + /HER2- breast cancer, but knowledge gaps remain, and further research is necessary to better define their optimal use.

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–36. https://doi.org/10.1056/NEJMoa1607303.CrossRefPubMed

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209–19. https://doi.org/10.1056/NEJMoa1505270.CrossRefPubMed

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926–36. https://doi.org/10.1056/NEJMoa1810527.CrossRefPubMed

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–48. https://doi.org/10.1056/NEJMoa1609709.CrossRefPubMed

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. https://doi.org/10.1038/s41523-018-0097-z.CrossRefPubMedPubMedCentral

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15. https://doi.org/10.1016/S1470-2045(18)30292-4.CrossRefPubMed

Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875–84. https://doi.org/10.1200/JCO.2017.73.7585.CrossRefPubMed

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72. https://doi.org/10.1200/JCO.2018.78.9909.CrossRefPubMed

•Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987–98. https://doi.org/10.1200/JCO.20.02514. The initial results of the phase 3 monarchE trial were presented in this article. This study showed that the addition of 2 years of abemaciclib to standard adjuvant ET resulted in significant improvement in iDFS in patients with high-risk HR+/HER2- eBC.

10.

Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020;21(6):1960. https://doi.org/10.3390/ijms21061960.CrossRefPubMedPubMedCentral

11.

Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–31. https://doi.org/10.1038/35106065.CrossRefPubMed

12.

Santo L, Siu KT, Raje N. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Semin Oncol. 2015;42(6):788–800. https://doi.org/10.1053/j.seminoncol.2015.09.024.CrossRefPubMed

13.

Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23(18):4215–24. https://doi.org/10.1200/JCO.2005.05.064.CrossRefPubMed

14.

Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.CrossRef

15.

Fornier MN, Rathkopf D, Shah M, Patil S, O’Reilly E, Tse AN, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007;13(19):5841–6. https://doi.org/10.1158/1078-0432.CCR-07-1218.CrossRefPubMed

16.

Marra A, Curigliano G. Are all cyclin-dependent kinases 4/6 inhibitors created equal? NPJ Breast Cancer. 2019;5:27. https://doi.org/10.1038/s41523-019-0121-y.CrossRefPubMedPubMedCentral

17.

Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016;15(10):2273–81. https://doi.org/10.1158/1535-7163.MCT-16-0300.CrossRefPubMed

18.

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–37. https://doi.org/10.1007/s10637-014-0120-7.CrossRefPubMedPubMedCentral

19.

Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321–30. https://doi.org/10.2147/DDDT.S137783.CrossRefPubMedPubMedCentral

20.

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46. https://doi.org/10.1038/nrd4504.CrossRefPubMedPubMedCentral

21.

Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66. https://doi.org/10.1038/nrc2602.CrossRefPubMed

22.

George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Front Oncol. 2021;12(11): 693104. https://doi.org/10.3389/fonc.2021.693104.CrossRef

23.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7. https://doi.org/10.1093/annonc/mdy155.CrossRefPubMed

24.

Schaeffer S, Lutz C, Dobbie M, Terracciano LM, Matter M, Vosbeck J, et al. Ribociclib-induced liver injury: a case report. Front Oncol. 2023;13:1256783. https://doi.org/10.3389/fonc.2023.1256783.CrossRefPubMedPubMedCentral

25.

Wani K, Patel K, Dabak V. Hepatotoxicity After CDK 4/6 Inhibitor Initiation in the Treatment of Hormone-Positive Metastatic Breast Cancer. Cureus. 15(6):e40871. https://doi.org/10.7759/cureus.40871

26.

Chappell JC, Turner PK, Pak YA, Bacon J, Chiang AY, Royalty J, et al. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019;105(5):1187–95. https://doi.org/10.1002/cpt.1296.CrossRefPubMed

27.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016;6(7):740–53. https://doi.org/10.1158/2159-8290.CD-16-0095.CrossRefPubMed

28.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218–24. https://doi.org/10.1158/1078-0432.CCR-17-0754.CrossRefPubMedPubMedCentral

29.

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116–24. https://doi.org/10.1001/jamaoncol.2019.4782.CrossRefPubMed

30.

•• Goetz M, Toi M, Huober J, Sohn JH, Tredan O, Park IH, et al. (GS01–12) MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer [Internet]. Oral presentation presented at: San Antonio Breast Cancer Symposium 2023; 2023 Dec 6 [cited 2023 Dec 29]; San Antonio, TX. Available from: https://sabcs2023.eventscribe.net/fsPopup.asp?PresentationID=1329789&returl=YWpheGNhbGxzL3Nlc3Npb25pbmZvLmFzcD9QcmVzZW50YXRpb25JRD0xMzM2NzI3&mode=presInfo. Accessed 29 Dec 2023. Final OS results of the MONARCH-3 trial were presented at the San Antonio Breast Cancer Symposium in December 2023 which showed a clinically meaningful but statistically not significant improvement in median OS with the addition of abemaciclib to NSAI as first line therapy in HR+/HER2- mBC.

31.

••Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022 Mar 10;386(10):942–50. https://doi.org/10.1056/NEJMoa2114663. Overall survival results from the phase 3 MONALEESA-2 trial, which showed statistically significant prolongation of OS with the addition of ribociclib to letrozole in the first line treatment of HR+/HER2- mBC. Given the consistent OS benefits seen across the MONALEESA trials, ribociclib is now the preferred first line CDK4/6i based on category 1 NCCN recommendations.

32.

••Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021 Aug;32(8):1015–24. https://doi.org/10.1016/j.annonc.2021.05.353. Updated OS results of MONALEESA-3, which showed OS improvement with the addition of ribociclib to fulvestrant in 1^st and 2^nd line treatment of HR+/HER2- mBC.

33.

Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307–16. https://doi.org/10.1056/NEJMoa1903765.CrossRefPubMed

34.

••Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [December 22, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org. Most recent update to the NCCN Breast Cancer Guidelines includes a category 1 recommendation for the use of ribociclib in combination with ET for the first line treatment of HR+/HER2- mBC.

35.

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35. https://doi.org/10.1016/S1470-2045(14)71159-3.CrossRefPubMed

36.

•Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419–28. https://doi.org/10.1007/s10549-020-05755-7. Overall survival results of the phase 2 PALOMA-1 trial which missed statistical significance to show the superiority of palbociclib plus letrozole versus letrozole alone in first line treatment of HR+/HER2- mBC.

37.

Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015;21(21):4760–6. https://doi.org/10.1158/1078-0432.CCR-15-1185.CrossRefPubMed

38.

••Finn RS, Rugo HS, Dieras VC, Harbeck N, Im SA, Gelmon KA, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. | J Clin Oncol. 40, no. 17_suppl (June 10, 2022) LBA1003-LBA1003. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1003. Overall survival results of the phase 3 PALOMA-2 trial which missed statistical significance to show the superiority of palbociclib plus letrozole versus letrozole alone in first line treatment of HR+/HER2- mBC.

39.

••Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022 Aug 15;28(16):3433–42. https://doi.org/10.1158/1078-0432.CCR-22-0305. Exploratory overall survival analysis of the phase 3 PALOMA-3 trial which missed statistical significance to show the superiority of palbociclib plus letrozole versus letrozole alone in first line treatment of HR+/HER2- mBC.

40.

•Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer. NPJ Breast Cancer. 2022 Oct 11;8(1):1–13. https://doi.org/10.1038/s41523-022-00479-x. Real-world study based on the Flatiron database showing significant overall survival benefit of palbociclib plus AI versus AI alone in the first line treatment of HR+/HER2- mBC.

41.

Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, et al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791–9. https://doi.org/10.1001/jamaoncol.2021.4301.CrossRefPubMed

42.

•Perez-Garcia J, Bellet-Ezquerra M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavilá J, et al. (RF01–03) PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study [Internet]. San Antonio Breast Cancer Symposium 2023; 2023 Dec 6 [cited 2023 Dec 30]; San Antonio, TX. Available from: https://sabcs2023.eventscribe.net/fsPopup.asp?Mode=presInfo&PresentationID=1327700. Accessed 30 Dec 2023. 5-year OS data of the PARSIFAL study presented at the 2023 San Antonio Breast Cancer Symposium showing mOS of 65 months with first line treatment with palbociclib (in combination with either letrozole or fulvestrant) which is on par with OS data for other CDK4/6i, suggesting similar effectiveness of palbociclib.

43.

Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Drug Metab Dispos. 2015;43(9):1360–71. https://doi.org/10.1124/dmd.114.062745.CrossRefPubMed

44.

Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020;26(20):5310–9. https://doi.org/10.1158/1078-0432.CCR-20-1764.CrossRefPubMed

45.

Yıldırım HÇ, Mutlu E, Chalabiyev E, Özen M, Keskinkılıç M, Ön S, et al. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study. Breast. 2022;30(66):85–8. https://doi.org/10.1016/j.breast.2022.09.009.CrossRef

46.

••Sonke GS, Van Ommen - Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017–03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2023 Jun 10;41(17_suppl):LBA1000–LBA1000. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA1000. Presentation of the initial results of the phase 3 SONIA trial at the 2023 ASCO Annual Meeting, which showed similar outcomes when CKD4/6i were added to ET in the first versus the second line setting, while also showing a substantial reduction in grade 3/4 toxicities and savings of around $200,000 per patient.

47.

Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 7(42):68012–22. https://doi.org/10.18632/oncotarget.12010.

48.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018;34(6):893-905.e8. https://doi.org/10.1016/j.ccell.2018.11.006.CrossRefPubMedPubMedCentral

49.

Condorelli R, Spring L, O’Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640–5. https://doi.org/10.1093/annonc/mdx784.CrossRefPubMed

50.

Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, et al. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. Cancer Discov. 2020;10(1):72–85. https://doi.org/10.1158/2159-8290.CD-18-0830.CrossRefPubMed

51.

Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020;10(8):1174–93. https://doi.org/10.1158/2159-8290.CD-19-1390.CrossRefPubMedPubMedCentral

52.

Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, et al. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Rep. 2023;42(11): 113198. https://doi.org/10.1016/j.celrep.2023.113198.CrossRefPubMedPubMedCentral

53.

Al-Qasem AJ, Alves CL, Ehmsen S, Tuttolomondo M, Terp MG, Johansen LE, et al. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. NPJ Precis Oncol. 2022;6(1):68. https://doi.org/10.1038/s41698-022-00311-6.CrossRefPubMedPubMedCentral

54.

Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol. 2019;37(14):1169–78. https://doi.org/10.1200/JCO.18.00925.CrossRefPubMedPubMedCentral

55.

Foldi J, Brufsky A. Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression. Ann Transl Med. 2023 Jun 30;11(9):327. https://doi.org/10.21037/atm-23-965.

56.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.CrossRefPubMed

57.

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058–70. https://doi.org/10.1056/NEJMoa2214131.CrossRefPubMed

58.

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246–56. https://doi.org/10.1200/JCO.22.00338.CrossRefPubMedPubMedCentral

59.

•Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023 Aug 20;41(24):4004–4013. https://doi.org/10.1200/JCO.22.02392. Results of the randomized phase 2 MAINTAIN trial showing promising PFS benefit to switching CDK4/6i to ribociclib and switching ET partner after progression on first line CDK4/6i plus ET in patients with HR+HER2- mBC.

60.

Mayer E, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. Abstract GS3–06: GS3–06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer. Cancer Res. 2023 Mar 1;83:GS3–06. https://doi.org/10.1158/1538-7445.SABCS22-GS3-06.

61.

Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz-Borrego M, Comerma L, et al. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clin Cancer Res. 2023;29(1):67–80. https://doi.org/10.1158/1078-0432.CCR-22-1281.CrossRefPubMed

62.

Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol. 2022;1(33):S1384. https://doi.org/10.1016/j.annonc.2022.08.009.CrossRef

63.

Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719–29. https://doi.org/10.1007/s10549-018-05125-4.CrossRefPubMedPubMedCentral

64.

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021;27(15):4177–85. https://doi.org/10.1158/1078-0432.CCR-20-2114.CrossRefPubMedPubMedCentral

65.

Pascual J, Lim JSJ, Macpherson IR, Armstrong AC, Ring A, Okines AFC, et al. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discov. 2021;11(1):92–107. https://doi.org/10.1158/2159-8290.CD-20-0553.CrossRefPubMed

66.

•Jhaveri K, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. GS03–13: Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis [Internet]. San Antonio Breast Cancer Symposium 2023; 2023 Dec 8 [cited 2023 Dec 29]; San Antonio, TX. Available from: https://aacr.ent.box.com/s/im3djx6fp13rad4kr3fmaf5ijj251pni. Presentation of the initial results of the INAVO120 phase 3 randomized trial that evaluated the triplet combination of inavolasib plus palbociclib plus fulvestrant as first line therapy in patients with PIK3CA-mutated HR+/HER2- mBC. This is the first phase 3 study to show PFS benefit and acceptable toxicity profile of a triplet combination including a CDK4/6i and a PI3K inhibitor. Further follow-up will be needed to determine if this novel combination will replace current standard of care first line therapy for this patient population.

67.

Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, et al. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. 2022;8(1):118. https://doi.org/10.1038/s41523-022-00482-2.CrossRefPubMedPubMedCentral

68.

Jerusalem G, Prat A, Salgado R, Reinisch M, Saura C, Ruiz-Borrego M, et al. Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. Breast. 2023;72: 103580. https://doi.org/10.1016/j.breast.2023.103580.CrossRefPubMedPubMedCentral

69.

Herold CI, Trippa L, Li T, Do K, Bardia A, Anderson L, et al. Abstract P3–14–03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR MBC) and metastatic ovarian cancer (MOC). Cancer Res [Internet]. 2020 [cited 2024 Mar 22];80(4_Supplement). Available from: https://findanexpert.unimelb.edu.au/scholarlywork/1818345-abstract-p3-14-03--a-phase-1b-study-of-the-cdk4-6-inhibitor-ribociclib-in-combination-with-the-pd-1-inhibitor-spartalizumab-in-patients-with-hormone-receptor-positive-metastatic-breast-cancer-(hr-mbc)-and-metastatic-ovarian-cancer-(moc). https://doi.org/10.1158/1538-7445.SABCS19-P3-14-03.

70.

Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). J Immunother Cancer. 2023;11(9): e007126. https://doi.org/10.1136/jitc-2023-007126.CrossRefPubMedPubMedCentral

71.

•Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021 Dec;32(12):1571–81. https://doi.org/10.1016/j.annonc.2021.09.015. Updated efficacy results of the adjuvant monarchE trial showing continued benefit of adjuvant abemaciclib plus ET over ET alone in patients with high risk eBC. This study also showed that Ki-67 was prognostic but not predictive of abemaciclib benefit, which led to the removal of the Ki-67 threshold from the FDA approval of abemaciclib for the adjuvant treatment of HR+/HER2- eBC.

72.

Research C for DE and. FDA expands early breast cancer indication for abemaciclib with endocrine therapy. FDA [Internet]. 2023 Mar 16 [cited 2023 Dec 27]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy. Accessed 27 Dec 2023

73.

••Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): resultsa from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Jan 1;24(1):77–90. https://doi.org/10.1016/S1470-2045(22)00694-5. Updated efficacy results of the adjuvant monarchE trial showing continued benefit of adjuvant abemaciclib plus ET over ET alone in patients with high risk eBC at a preplanned landmark interim analysis.

74.

••Hortobagyi GN, Stroyakovskiy D, Yardley D, Huang CS, Fasching PA, Crown JP, et al. (GS03–03) Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial [Internet]. San Antonio Breast Cancer Symposium 2023; 2023 Dec 8 [cited 2023 Dec 30]; San Antonio, TX. Available from: https://sabcs2023.eventscribe.net/fsPopup.asp?Mode=presInfo&PresentationID=1335761. Final iDFS results of the phase 3 NATALEE trial presented at the 2023 San Antonio Breast Cancer Symposium showing significant improvement in iDFS rate with the addition of 3 years of ribociclib to standard ET in stage II-III eBC.

75.

Dennis S, Oleg L, Zbigniew N, Nicholas McAndrew, Bozena K-B, Daniil S, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080–91. https://doi.org/10.1056/NEJMoa2305488.CrossRef

76.

Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021;39(14):1518–30. https://doi.org/10.1200/JCO.20.03639.CrossRefPubMed

77.

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40(3):282–93. https://doi.org/10.1200/JCO.21.02554.CrossRefPubMed

78.

Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, et al. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Curr Treat Options Oncol. 2021;22(9):79. https://doi.org/10.1007/s11864-021-00879-4.CrossRefPubMed

79.

Stover DG, Hlauschek D, Mayer E, Symmans WF, Watson M, Barozzi I, et al. (GS03–07) Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer. [Internet]. San Antonio Breast Cancer Symposium 2023; 2023 Dec 8 [cited 2023 Dec 30]; San Antonio, TX. Available from: https://sabcs2023.eventscribe.net/fsPopup.asp?Mode=presInfo&PresentationID=1328546. Accessed 30 Dec 2023

80.

ASCO [Internet]. 2023 [cited 2023 Dec 29]. ASCO Awarded $11M to Study Oral Drug Dosing Strategies in Older Adults with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors. Available from: https://old-prod.asco.org/about-asco/press-center/news-releases/asco-awarded-11m-study-oral-drug-dosing-strategies-older. Accessed 29 Dec 2023

81.

Hart L, Im SA, Tolaney SM, Campone M, Pluard TJ, Sousa B, et al. (PS02–01) Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials [Internet]. San Antonio Breast Cancer Symposium 2023; 2023 Dec 5 [cited 2023 Dec 30]; San Antonio, TX. Available from: https://sabcs2023.eventscribe.net/fsPopup.asp?Mode=presInfo&PresentationID=1328914. Accessed 30 Dec 2023

82.

Murphy R, Halford S, Symeonides SN. Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective. Front Oncol. 2023;3(13):1144056. https://doi.org/10.3389/fonc.2023.1144056.CrossRef

83.

Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O’Connor T, et al. Determinants of response to CDK4/6 inhibitors in the real-world setting. Npj Precis Oncol. 2023;7(1):1–17. https://doi.org/10.1038/s41698-023-00438-0.CrossRef

84.

Yap TA, Giordano A, Hamilton EP, LoRusso P, Bowers M, Basu C, et al. First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy. J Clin Oncol. 2023 Jun;41(16_suppl):3009–3009. https://doi.org/10.1200/JCO.2023.41.16_suppl.3009.

85.

Hurvitz SA, Andre F, Cristofanilli M, Curigliano G, Giordano A, Han HS, et al. A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1). J Clin Oncol. 2023 Jun;41(16_suppl):TPS1118–TPS1118. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS1118.

86.

Roy T, Barrows E, Mainor C, Collins J, Lynce F, Isaacs C, et al. A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor. Contemp Clin Trials Commun. 2023;33: 101110. https://doi.org/10.1016/j.conctc.2023.101110.CrossRefPubMedPubMedCentral

87.

Dietrich C, Trub A, Ahn A, Taylor M, Ambani K, Chan KT, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023. https://doi.org/10.1158/2159-8290.CD-23-0954.CrossRefPubMedCentral

88.

Patel MR, Juric D, Henick BS, Duska LR, Wu R, Guo J, et al. BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation. J Clin Oncol. 2023 Jun;41(16_suppl):3095–3095. https://doi.org/10.1200/JCO.2023.41.16_suppl.3095.

Titel: CDK4/6 inhibitors: The Devil is in the Detail
verfasst von: Tara Magge
Sneha Rajendran
Adam M. Brufsky
Julia Foldi
Publikationsdatum: 07.05.2024
Verlag: Springer US
Erschienen in: Current Oncology Reports
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01540-7

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen